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Conference Report: Gynecologic Cancer Outcome
Improves Because of New Treatment Applications
by Ralph S. Freedman, M.D., Ph.D.
Associate Professor and Director of
Research, Department of Gynecology
The 29th Annual Clinical Conference of the U.T. M. D. Anderson
Hospital and Tumor Institute last
November was devoted to reviewing
progress in the treatment and diagnosis of gynecologic cancers.
Speakers from the Houston cancer
center were joined by clinicians and Ralphs. Freedman
researchers from universities and
hospitals in the United States and Canada. Many noted
significant improvements in the administration of conventional therapies, accompanied by an increase in survival rates
generally and a decrease in treatment-related deaths from several
types of cancer. The papers given at the conference are
scheduled to be published later this year by the University of
Texas Press; here I will concentrate on some of the discussions
led by MDAH colleagues.

Heath Lecture on Exenteration Experience
Felix N. Rutledge, M.D., professor and
head, Department of Gynecology, gave
the Heath Memorial Lecture in which he
reviewed the UT MDAH experience with
pelvic exenteration in gynecologic cancer
treatment. This operation, in which either
bladder or rectum or both are removed
together with the vagina and portions of
the vulva, is the most radical surgical
Felix N. Rutledge
procedure employed by gynecologic oncologists. It is used only when. less severe therapies have failed or
are predicted to fail. The operation is used mainly but not
exclusively for treating recurrent uterine cervical cancer, and
it is rarely recommended until after irradiation has been tried.
The recent literature indicates a decline in the number of
exenterations performed, yet the incidence at UT MDAH has
remained constant, for reasons that are not clear, Rutledge said.
He reported on 448 patients who underwent this procedure
here between 1955 and 1984, noting significant reductions in
postoperative mortality, more long-term survivors, and improved
restoration of patients' sexual function. Postoperative morta-

lity declined from 13.5% among the 296 earlier (1955-1976)
patients to 3.9% of the 152 later (1977-1984) patients, and 53%
of the patients survived five years or longer. New techniques
for preoperative identification of metastases and more precise
criteria for choosing patients who will benefit from exenteration have reduced the incidence of incomplete resections.
The current method of vaginal reconstruction seems to be
successful. Myocutaneous grafts taken from a segment of
gracilis muscle, an island of skin, and subcutaneous tissue from
the medial thigh serve several purposes: vaginal restoration,
perinea! support, cosmetic normalcy, and faster healing of the
perinea! defect.
Rutledge's conclusion was that pelvic exenteration is successful as a salvage treatment, especially when the five-year survival
rate is compared with that of patients undergoing primary
surgical treatment for cancer at other body sites.

Radical Compared with Conservative Surgery
Radical surgery for gynecologic cancer
was discussed also by Creighton L.
Edwards, M.D., professor and holder of
the Ann Rife Cox Chair in Gynecology.
Radical vulvectomy and bilateral groin
lymphadenectomy, with or without pelvic lymphadenectomy, is the traditional
treatment for carcinoma of the vulva, he
said. Radical surgical intervention early in Creighton L Edwards
the disease does not, however, protect
against local recurrence and may produce high postoperative
morbidity.
In contrast, Edwards said, conservative surgical techniques
such as wide local excision or hemivulvectomy and ipsilateral
groin dissection do not increase the recurrence risk, and they
are associated with shorter hospital stays, fewer wound breakdowns and infections, less chronic leg edema, and fewer
psychosocial consequences. Moreover, the corrected survival
figures for patients with stages I and II squamous carcinoma of
the vulva treated with standard radical methods, compared
with survival rates of patients treated by conservative surgical
methods, are not statistically different.
Edwards suggested that if the vulva is otherwise normal, wide
local excision is appropriate treatment for the primary lesion
continued on page 2
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regardless of depth of invasion. If there is stromal invasion of
more than 1 mm and the lesion is unilateral, only an ipsilateral
groin lymphadenectomy is necessary. If test results of the
ipsilateral nodes are positive, dissection or irradiation of the
contralateral nodes may be appropriate.

Epithelial Ovarian Cancer
In a minisymposium on treatment for
epithelial ovarian cancer, J. Taylor
Wharton, M.D., deputy head, Department
of Gynecology, reported th~t long-term
remissions are most likely in patients who
have only minimal residual disease in the
abdomen after initial surgery. An analysis
of patients with stage III disease showed
that the most favorable results occurred in
J. Taylor Wharton
patients whose lesions were 2 cm or smaller
when therapy began. If these patients' tumors can be reduced
further with chemotherapy, additional therapy such as
irradiation of the entire abdomen or intraperitoneal injections
of biological response modifiers-for example, viral
oncolysates-may be considered.
David M. Gershenson, M.D., associate professor, Department
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of Gynecology, whose primary interest is the chemotherapy of
epithelial tumors, germ cell tumors, and stromal tumors of
ovarian origin, reviewed the status of chemotherapy for
advanced epithelial ovarian cancer.
Combination chemotherapy seems to be superior to singleagent therapy, cisplatin-containing regimens being the ones
most widely used. Preliminary information suggests that twodrug combinations may be as effective as three- and four-drug
regimens. Second-line therapy for patients with refractory
ovarian cancer continues to have poor results, he said.

Second-Look Laparotomy
Larry J. Copeland, M.D., associate professor, Department of
Gynecology, reviewed the UT MDAH experience with secondlook laparotomy, a procedure that is usually performed between
six and 12 months after the initial surgery for ovarian cancer.
Current treatment programs leave 50% to 60% of patients who
had advanced disease clinically free of cancer. Second-look
laparotomy has shown about 30% of these patients to have no
evidence of disease, about 20% to have persistent tumor that
is identified only microscopically, and about 50% to have
macroscopically identifiable tumor. The five-year survival rate
of patients whose second-look laparotomy produces negative or
microscopic positive findings is about 70%, compared with 10%
to 15% of patients who have macroscopic positive findings.
When well-differentiated lesions are excluded from analysis,
however, the recurrence rate is about 50% for patients with
either negative or microscopic positive second-look findings.
Copeland expressed the hope that
innovations in therapy would sustain or
complete the tumor response in this
patient group. For patients with
macroscopic tumor at second-look
laparotomy the prognosis is dismal, and the
value of debulking persistent tumors has
not been proved.

Gynecologic Cancer Research

Larry J. Copeland

Ovarian cancer, today the major cause of gynecologic cancerrelated deaths, is the focus of intensive clinical and laboratory
research. I described my group's trials with intraperitoneal
injection of new immunotherapeutic agents in patients with
advanced ovarian cancer. In collaboration with James M.
Bowen, Ph.D., professor of virology and vice president for
academic affairs, we developed an immunogenic "vaccine" of
viral oncolysates, which are extracts of cultured ovarian
carcinoma cells whose antigenicity is altered by the
incorporation of a harmless virus before the cells are disrupted.
When we tested these extracts in 40 patients whose advanced
ovarian cancer had not responded to conventional therapy, nine
patients responded, including seven in whom malignant ascites
disappeared and two in whom the tumor masses decreased.

continued on page 4
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Counseling, Practical Advice Help Women with
Cervical Cancer Resume Sexual Activity
on the causes of cervical cancer and
Patients can be as sexually active after treatment for cervical
the fact that the disease is not
cancer as they were before the illness was diagnosed, but many
contagious. Resuming her sex life
are unable to do so without counseling and practical advice,
won't cause cancer to recur. We give
according to Leslie R. Schover, Ph.D. , assistant professor of
the patient some ideas on how to
urology (psychology) and assistant clinical psychologist at UT
resume sex comfortably. We let her
MDAH.
know that she should still be able to
Sexual counseling for these patients " needs to be a routine
reach orgasm, and that the cancer
part of patient care. All women should be screened for sexual
treatment should not impair her
problems because perhaps one woman in 10 is willing to ask
ability to feel pleasure." Women
a physician for help," she said.
undergoing radiotherapy are told
Preliminary results of a study done here by Schover and
about lubricants to use for vaginal Leslie R. Schover
colleagues Michael Fife, M.S.W. , and David M. Gershenson,
dryness and about comfortable use of
M.D., show that women who receive counseling along with
the vaginal dilators they may need.
cancer therapy have the same rate of sexual activity and sexual
" Couples may have to try new types of caressing or positions
satisfaction they had before the disease was diagnosed. These
for
intercourse, " Schover said. She sometimes recommends
results are in contrast to those from studies of patients elsewhere
general
self,help books, for example, For Yourself and For Each
who had no counseling and whose rates of sexual dysfunction
Other by Lonnie Barbach (Anchor Press, 1974 and 1982) or
and marital dissolution increased dramatically after cancer
Becoming Orgasmic by Julia R. Heiman, Leslie LoPiccolo, and
treatment. So far, the MDAH study has included 51 women.
Joseph LoPiccolo (Prentice,Hall, 1976).
As Schover explained, "I like to see the patients when they
Using three,dimensional models, she shows patients the parts
are just beginning their cancer treatmen t . That's the best time,
of the body involved in sexual activity and their function both
at least for preventive counseling, because I can alleviate their
before and after cancer treatment.
anxieties before their relationships become affected and make
sure that they have the information they need to stay sexually
Resume Normal Sex Life? Yes.
active during treatment and afterward."
When patients ask if they can have a normal sex life after
Since Schover is the sole sex therapist on the hospital staff,
their treatment for gynecologic cancer, Schover says
however, she can counsel only a small percentage of the women
emphatically, "Yes, you can." She explains that the patient
treated here annually for gynecologic cancer.
"I get to know the woman and her background and history,
may experience some mild discomfort and some symptoms from
how she feels about the cancer, how much the illness affects
the cancer treatment. If the patient has had a hysterectomy,
her daily life, how much family support she has, and how her
for example, her vagina may feel shorter at first, and if she has
children are being cared for during the
had radiotherapy, she may, in rare instances,
cancer treatment." Schover said.
have problems with radiation ulcers. The
Don't assume that
She asks about "all those different things
majority of patients who have undergone
that affect the woman's ability to cope , as
if the patient doesn't ask, radiotherapy will experience less lubrication
well as her sexual history- whether she has
during intercourse. The vagina will not be
she doesn't have
had difficulties in the past with low sexual
able to expand as much as previously, so it
a problem.
desire, for example, or painful intercourse,
may feel dry or tight.
or not being able to reach orgasm."
"That's why vaginal dilation and frequent
Schover spends at least a couple of hours in one or two sessions
intercourse are important during the healing period after
with the patient, and when possible she likes to meet with both
radiation therapy, along with using adequate lubricants for
members of a couple. Her semistructured interviews include the
intercourse. Even women who have had a total pelvic
use of formal questionnaires-for example, the Brief Symptom
exenteration and a neovagina created with myocutaneous
Inventory, a measure of psychological distress, and a multiple,
gracilis flaps can resume intercourse if they want to," she
choice questionnaire on sexuality.
explained.
An important topic often overlooked in counseling cancer

Education and Advice
"To allay common fears, " she said, "I counsel the woman
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These results are comparable to those of intraperitoneal
administration of Corynebacterium parvum and interferon
reported by others, and the toxicity of viral oncolysates seems
to be less than expected.
In a related report, Eva Lotzova, Ph.D.,
professor of immunology and chief of the
Section of Immunogenetics, Department
of General Surgery, described her research
with natural killer (NK) cells, which are
large granular lymphocytes considered
important in the defense against various
types of cancer. She demonstrated that
Eva Lotzova
ovarian cancer patients have low NK cell
antitumor potential in peripheral blood
and virtually no cytotoxicity in peritoneal fluid. Her investigations have opened new avenues to correcting NK cell defects
in these patients.
lntraperitoneal injections of viral oncolysates into ovarian
cancer patients resulted in 60% to 80% tumor cell lysis and
caused sustained potentiation, for seven to 21 days, of NK cell
antitumor activity in the patients' peritoneal fluids. Viral
oncolysate-induced NK cell activity reflected both the increase
in the number of NK cells and augmentation of these cells'
lytic activity. Along with regional augmentation of NK cells
came regression of malignant ascites. Viral oncolysates
administered intraperitoneally were not always effective in
augmenting peripheral blood NK activity; Lotzova reported,
however, that peripheral blood NK activity could be stimulated in culture with interleukin-2 (IL-2) within three to seven
days.

Regional augmentation of
NK cells was accompanied by
regression of ascites.
Because of these prommng results, patients who have
persistent but relatively small-volume disease at second-look
aparotomy will now be eligible to receive intraperitoneal
immunotherapy with viral oncolysates. In addition, Lotzova and
I have begun working on a new clinical protocol that involves
treatment with intraperitoneal oncolysates in combination with
adoptive transfer of IL-2-activated autologous NK cells.

Endometrial Cancer
In his report on treatment of endometrial cancer, Luis Delclos,
M.D., professor of radiotherapy, said that, beginning in 1969,
58 patients with minimal disease and well-differentiated tumors
(stage IA, grade 1) were treated with one intracavitary radium

4

insertion followed by an extrafascial
hysterectomy at the same admission. The
results at three years were encouraging,
and in 1978 it was decided to simplify
treatment for all patients with stage IA,
grade 2, and stage IB, grade 1, disease.
Delclos showed data on 53 patients
with stage IA, grade 2, and stage IB,
grade 1, endometrial cancer who had Luis Delclos
responded favorably to treatment with
either one radium insertion and hysterectomy at the same
admission or with two radium insertions three weeks apart and
hysterectomy six weeks later. The results were comparable100% and 90% five-year and longer survivals for grade 1 and
grade 2 patients, respectively-and therefore the single-radium
technique has become the technique of choice. Only one patient
in the group experienced a vaginal cancer recurrence.
The second group of 37 patients, who had grade 3 (stage IA
plus IB) and grade 2 (stage IB) tumors, were treated with two
radium insertions three weeks apart and hysterectomy six weeks
later or with external irradiation (4,000 rad/4 weeks) plus one
radium insertion followed by hysterectomy. Results were the
same for both groups; 50% of the patients died because of
progressive disease.

Combined Therapies for Pelvic Tumors
Joseph S. Kong, M.D., assistant professor of radiotherapy,
reported on a new study to examine the role of combined
hyperthermia and irradiation in patients
with advanced pelvic cancer. Four of six
patients with metastatic gynecologic
cancers achieved a complete tumor
reponse for 10 to 52 weeks after treatment
with radiation and ultrasound or magnetic
induction heating. A pilot study of the
effectiveness of interstitial hyperthermia
and irradiation for deep pelvic tumors Joseph s. Kong
began this year. Of the four patients with
recurrent cervical carcinoma treated so far for alliation. two
achieved complete pain relief, one for two and the other for
six months.

Tumor Markers
Herbert A. Fritsche, Ph.D., professor of clinical chemistry,
Department of Laboratory Medicine, discussed an array of new
tumor markers being evaluated for diagnosing ovarian and
uterine cancer. New immunoassay test procedures employing
monoclonal antibodies are being developed for alpha-fetoprotein
and human chorionic gonadotrophin (HCG) to improve the
tests' specificity. The tests are needed to establish the clinical
April-June 1986

Thirty,ninth Annual Symposium on Fundamental Cancer Research

Critical Molecular Determinants in Carcinogenesis

-

The Thirty-ninth Annual Symposium on Fundamental Cancer
Research, Critical Molecular Detenninants in Carcinogenesis, will be
chaired by Frederick F. Becker, M.D., vice president for research, and
Thomas J. Slaga, Ph.D., director of the Science Park-Research Division
of the UT System Cancer Center. Following is Becker's prospective
view of the conference:
The enormous advances recently attained in the areas of molecular
and cellular biology make it possible to analyze the complex process
of carcinogenesis for critical molecular determinants. Carcinogenesis
is the sequential induction of a series of cellular alterations by chemical,
physical, or viral agents, which results in the appearance of the
abnormal and damaging cell known as a cancer cell.
This symposium is aimed at bringing together experts in these crucial
and relatively new areas of scientific investigation in an attempt to
synthesize a picture of the carcinogenic process at the molecular level.
Among the topics to be emphasized will be the crucial role played
by the genetic makeup of the target cell in terms of its susceptibility
to carcinogenic agents, the expression of oncogenes, and the role played
by exogenous agents in promoting this process.
New technological advances such as the use of transgenic micemice that arise from a normal embryo into which a foreign gene has
been injected-will be prominently discussed at the meeting. Instead
of the usual broad approach to the role of oncogenes, the conference
organizers chose to use ras as the model for function of this class of
abnormal genes.
The final session will concentrate on the intracellular signals that
control normal function of a cell and that may become aberrant under
the influence of oncogenes or other factors. Abnormalities in these
normal intracellular signals may result in the phenotype known as
cancer.
Free discussion and interchange will take place throughout the
meeting. In addition to the program components now listed, an attempt
will be made during the last three months before the meeting to add
brief presentations of the most advanced findings available.

September 16-19, 1986
Stouffer's Greenway Plaza Hotel
6 Greenway Plaza East, Houston 77046
(713) 629-1200

Sept. 16

(evening) Registration, Bettner Memorial
Lecture, reception.

Sept. 17

Morning sessions on the carcinogenic
process-cellular and molecular mechanisms, chromosomal
alterations, genetic determinants, genetic events and transformation.
Afternoon sessions on transgenic expression-transgenic
carcinogenesis, insertional mutation, globin genes, immunoglobulin
genes.

Sept. 18

Morning sessions on oncogenic expression-cell
cycle expression, developing systems (Drosophila), developing
mammalian systems, sequential expression in malignancy. Afternoon
sessions on oncogene function with ras as the model-yeast,
G protein, biologic effect of ras mutation, G protein-activated
mutation sites.

Sept. 19

Morning sessions on intracellular signaling-protein
kinase C, phospholipase C, adenotriphosphatase-ion flow, phorbol
ester receptors.

Please fill out registration form. (It is not a self-mailer.) Please address envelope and ~il registration and your remittance to:

Office of Conference Services-HMB Box 131
U.T. M. D. Anderson Hospital and Tumor Institute
6723 Bettner Avenue, Houston, Texas 77030
w .;;;;,:,rn rnm'

(713) 792-2222

:m
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Thirty-ninth Annual Symposium on Fundamental Cancer Research

CRITICAL MOLECULAR DETERMINANTS IN CARCINOGENESIS
LAST NAME

FIRST NAME

I I I
I II I

I I I
I I
□
I I

TinENAME

INSTITllTION

HIGHEST
DEGREES

I I
□
I I

BACH.

Ml

D Desire AMA credit
SOCIAL SECURITY NUMBER

I I I I I I I
SPECIALTY

I I I I
□
I I

MASTER'S

M.D.

I I
□
I I

□ $150 advance registration fee enclosed

I I
Ph.D

D

Other _ _ _ __

I I

CITY

BUSINESS PHONE

STATE OR FOREIGN COUNTRY

D $17 5 registration fee enclosed
(for registrations received after 8/15/86)
D Will pay on arrival
($17 5 on-site registration fee)

STREET

I I I
~I~
1~1~1~1~_i_~___L_L_1~1~ I I I I I I I I
I II I I
I I I I I

D Wed. D Thurs. D Fri.

ZIP CODE

DEPARTMENT/UNIT

Houston Hotel _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
or Local Address _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Phone _ _ _ _ _ _ _ _ _ _ __
Signatur e -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - THIS FORM MAY BE REPRODUCED

D $125 registration fee for
U.T. M. D. Anderson Associate enclosed
D Exempt (UT full-time faculty, students,
fellows, residents, and students from other
universities with identification)
D $45 optional fee for exempt participants
and guests enclosed (covers all written
materials, two lunches, receptions,
banquet, and coffee breaks)
Make check payable to
The University of Texas System Cancer Center

Thirtieth Annual Clinical Conference on Cancer

Current Approaches to the Diagnosis and Treatment
of Gastrointestinal Cancer
Gastrointestinal cancer causes more deaths and more pain than any
other cancer, Bernard Levin, M.D., chief of the Section of
Gastrointestinal Oncology and Digestive Diseases, said about the disease
that is the topic of the clinical conference he will chair Nov. 11-15,
Current Approaches to the Diagnosis and Treatment of Gastrointestinal
Cancer.
In its eight sessions with about 45 lectures and panel discussions,
the conference will provide information on the best in diagnosis and
treatment of this type of disease. It will be a fqrum for sharing new
ideas and learning about advances.
"We hope to appeal to a broad range of internists, family physicians,
gastroenterologists; medical and radiation oncologists, and surgeons,"
Levin said.
A Saturday session follows the regular conference, this one organized
by pathologists and addressed by the winner of the Joanne Vandenberge
Hill Award and William 0. Russell Lectureship in Anatomical
Pathology.
Similarly, the preceding sessions will have special lectures by
recipients of the Heath Memorial and the Jeffrey A. Gottlieb Memorial
Lecture awards. "We are awaiting the nominations for these awards
with great interest," Levin said.
Holding the meeting at the Hotel Inter-Continental in the Galleria
area is a change of scene from the Shamrock Hilton, which will close
this summer. The new site, about eight miles from the Texas Medical
Center, might be attractive, Levin said, to physicians and family
members who like to visit this outstanding commercial center.
Mayor Kathy Whitmire or Councilman George G reanias will address
the conference and, as Levin said, "give recognition to the importance
of this conference and to M. D. Anderson Hospital's contribution to
graduate education, and acknowledge the importance of Houston as
a center of higher education and medical research."

November 11-15, 1986
Hotel Inter-Continental, Galleria
5150 Westheimer, Houston 77056
(713) 961-1500
NOV•

11

(evening) Registration, wine and cheese party.

12

NOV•
Morning and afternoon sessions on large bowel
cancer-primary and secondary prevention, special risk groups, biology
and diagnosis; Heath Memorial Lecture. Opening day reception.

Nov. 13

Morning sessions on adjuvant chemotherapy,
immunotherapy, and radiation therapy of large bowel cancer; new
treatments for early rectal cancer; resection and natural history of
hepatic metastases; Gottlieb Lecture; and special lunchtime program
on American Cancer Society Colorectal Check Program. Afternoon
sessions on esophageal cancer.

NOV•

14

Morning sessions on pancreatic and hepatobiliary
cancer with case presentation panel; overview of hepatocellular cancer
and its relationship to hepatitis virus; biology, epidemiology, and current
management of gastric cancer. Afternoon sessions on biology and new
approaches to therapy of carcinoid tumors; hepatic arterial embolization
in endocrine tumors; new drugs for solid tumors; monoclonal antibodies
in diagnosis; and new applications of biological response modifier
therapy.

15

NOV•
Pathology session and Joanne Vandenberge Hill
Award and William 0. Russell Lecture in Anatomical Pathology.
Optional program on flexible sigmoidoscopy (for further information
on location and cost, call 713-792-2200).

Please fill out registration form. (It is not a self-mailer.) Please address envelope and mail registration and your remittance to :

Office of Conference Services-HMB Box 131
U.T. M. D. Anderson Hospital and Tumor Institute
6723 Bettner Avenue, Houston, Texas 77030
(713) 792-2222
Thirtieth Annual Clinical Conferen ce on Cancer
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(for registrations received after 10/20/86)
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($325 on-site registration fee)
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Houston Hotel _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
or Local Address _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Phone _ _ _ _ _ _ _ _ _ _ __
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D $250 registration fee for
U .T . M. D. Anderson Associate enclosed
D Exempt (UT full-time faculty, students,
fellows, residents, and students from other
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D $75 optional fee for exempt participants
enclosed (covers all written materials ,
three lunches, receptions, coffee breaks)

Make check payable to
The University of Texas System Cancer Center

significance of various forms of circulating HCG (alpha and beta
chains, hyper, and hypoglycosylated HCG) in the serum of
patients with germ cell tumors. Carcinoembryonic antigen,
Fritsche said, has h ad minimal application to gynecologic
cancer. It seems to be a useful tumor marker only for patients
with undifferentiated mucinous adenocarcinoma of the ovary,
but it may have prognostic value in adenocarcinoma of the
uterine cervix.

Carcinoembryonic antigen
has had minimal application
to gynecologic cancer.
Several new tumor markers have become available for
gynecologic cancer, one of which is tumor antigen 4 (TA-4),
a glycoprotein isolated from cervical squamous cell carcinoma.
Early studies suggest that 50% of patients with this type of cancer
may have elevated serum T A-4 levels.
Another marker is cancer antigen 125
(CA-125),
high-molecular-weight
glycoprotein that is present in the
circulation of 60% to 80% of patients with
epithelial ovarian cancers. CA-1 25 has
received considerable study, and it seems
to be useful for assessing a patient's
response to therapy and for detecting Herbert A. Fritsche
disease recurrence early. The cancer
antigen 19-9 (CA-19-9), a h igh-molecular-weight mucin
expressed by ovarian carcinomas, may in turn be a useful tumor
marker for patients whose tumors do not produce CA-125.
Fritsche reported on a variety of putative tumor markers,
among them NB/70K, which is a 70,000 molecular weight
glycoprotein produced by all histologic cell types of ovarian
epithelial tumors and may be a useful adjunct to the CA-125
test.

a
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patients is contraception, and this should be discussed before
the cancer treatment, Schover said, recalling that tragic
pregnancies have occurred during treatment because patients
thought they were infertile. This is not usually a problem for
women with cervical cancer, but it is relevant to young women
who undergo chemotherapy, she said.

Training Counselors
When no counselors trained in sex therapy are available,
Schover recommends that physicians advise patients themselves
or train a social worker or oncology nurse to do it. "Physicians
should not assume that if the patient doesn't ask, she doesn't
have a problem and doesn't need education," Schover said.
Those who have little training in sexuality might want to go
to a workshop on sex therapy, she advised. She recommends
such basic textbooks as The New Sex Therapy by Helen S. Kaplan
(Brunner/Maze!, 1974). "Whoever does the counseling,"
Schover said, "needs practice to feel comfortable discussing
sexuality with patients and to avoid being judgmental. The point
is that patients do what feels right for them."

Counseling Should Be Offered All Patients

Some of the quality of life questions for cancer patients were
discussed by Leslie R. Schover, Ph.D. , who said that women
treated for gynecologic cancer are at risk of sexual dysfunction.
Most of these problems can be prevented or at least alleviated
by brief sexual counseling and appropriate medical intervention.
Her report is the topic of an article in this issue.

Schover noted that in the current study at MDAH
participation was offered to all stage I through stage IIA cervical
cancer patients. The typical patient in the study is in her late
twenties or early thirties, comes from a lower-middle-class
background, and has had a "life of turmoil" that may have
included physical and sexual abuse. Several of the women have
been raped and some of their children have been sexually abused
by the women's husbands. Few of the women are heavy drinkers
or drug users, but at least a third of them have lived with men
who are, she said.
She stressed the importance of making sexual counseling
available to all patients undergoing treatment for gynecologic
cancer. "Ask a question about the patient's sex life and give
her the opportunity to tell you if she's having problems," she
recommended. "Many physicians don't do this," Schover said,
"because, unfortunately, most physicians really don't have much
training in asking about these things. All physicians who treat
these patients should be familiar with what happens to patients'
sex lives afterwards. It's a matter of taking the time and energy
to ask them.''

(Physicians who desire additional information may write Ralph S.
Freedman, M.D., Department of Gynecol.ogy, Box 67, The
University of Texas M. D. Anderson Hospital and Tumor Institute
at Houston, 6723 Bertner Avenue, Houston , Texas 77030.)

(Physicians who desire additional information may write Leslie R.
Schover, Ph.D., Department of Urology , Box 110, The University
of Texas M. D. Anderson Hospital and Tumor Institute at Houston,
6723 Bertner Avenue, Houston, Texas 77030.)
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A Geneticist's View of Cancer:
New Insight from Developmental Mechanisms
control over optional gene expression in a cell. If that cell is
not properly positioned in an embryo to respond to the
differentiation signals examined by
that particular program gene, the cell
duplicates its genome-its set of
We have been struggling to understand the basic difference
chromosomes-and divides. In the
between a normal cell and a cancer cell. Without that
resulting two daughter cells, the next
knowledge, our attempts at cancer therapy have been developed
gene in the program is the active
empirically, as we search for agents that can selectively destroy
control
gene. In this way, successive
cancer cells. If we knew the defect in a cancer cell, it might
be possible to bypass or correct it and to cure cancer by
cell divisions move control along the
transforming malignant cells into normal cells. Whether this
program from gene to gene, the way
goal is achievable remains to be seen, but the importance of
the clock in a computer paces a proa fully developed theoretical framework is clear.
gram from one instruction to the next.
The defect in cancer is hidden in the mechanism that controls
Only genetic functions unique to Elton Stubblefield
the behavior of normal cells. Before we can understand this
specialized cells are controlled by the
defect, we must comprehend the control mechanisms that
developmental program. Most genes encode proteins that are
govern embryonic development and differentiation. Until
essential to life in all cells, and these are regulated by feedback
recently, I believed embryonic development to be so complex
mechanisms similar to those found in bacteria. But the quite
that it would probably not be understood at the molecular level
different appearance and behavior of, for example, a neuron
until well into the next century. Yet recent discoveries in the
compared with a leukocyte rest in an array of specialized gene
genetics of development gave us evidence for a theoretical
products unique to each cell type. These are the genes regulated
framework that might be applied to malignant disease, at least
by the developmental control program.
in principle.
Another p~inciple in the theory is conditional control. In every
cell, the newly activated control gene must first ascertain the
Role of Control Genes
suitability of the cellular environment for expression or repression
The important discoveries in developmental biology all point
of the genes under its control. It does so by making cell surface
to a direct role of control genes in embryonic processes.
proteins, which are specific receptor molecules for embryonic
Mutation of control genes in Drosophfla melanogaster, a fruit fly,
inducers, hormones, and growth factors. When these appropriate
and in Caenorhabditis elegans, a nematode, produces altered
molecules are present in the environment, specific enhancers or
developmental patterns that result in abnormal embryos or
repressors are made by the cell to control the array of genes needed
adults. In a very striking case in Drosophila,
at that point in development.
mutation of the gene called Antennapedia
In relation to cancer, the proposed control
Discoveries in
results in an adult fly with thoracic legs
mechanism's
critical feature is that with
developmental biology
each genome replication and mitosis, conprotruding from the head where antennae
point to direct role
normally belong. Drosophila is known to
trol is transferred from one gene to the next
of control genes in
have several gene clusters of this kind.
in the developmental program. But in leuIn 1978 E. B. Lewis described a specific
kemia, for example, the cells behave as if
embryonic processes.
control gene cluster as a series of eight large
they were arrested in develppment in a
genes in a row, and since then molecular geneticists have
partly differentiated state, each daughter cell repeating parental
confirmed that mutation of any gene in such a cluster alters
behavior and failing to progress to the next part of the program.
the developmental pattern of Drosophila. The evidence from
The molecular defect is that the same program instruction is
many experiments in embryology led me to propose a genetic
repeated generation after cell generation.
mechanism by which these control genes are activated
Two Genetic Errors
sequentially as the developmental program unfolds in
embryogenesis. I wrote about this in greater depth than is
My theory is that the decision-making apparatus makes two
possible here in the Journal of Theoretical Biology (118: 129-143,
kinds of errors. One type of error occurs when the control gene
decides to pass control to the next cell generation and, without
1986).
Theoretically, the developmental control mechanism works
appropriate testing of cellular status or environment, sends the
this way: The first gene in one part of the program has potential
cell through DNA replication and mitosis. In the second error,

by Elton Stubblefield, Ph.D.
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the defective control gene fails to pass control to the next gene
control gene queries the environment, it probably receives an
in the sequence and retains control itself. The simultaneous
answer mediated by DNA,binding proteins, either enhancers
presence of both errors is necessary for a full,blown malignant
or repressors. If these are inappropriately altered by protein
disease, because if the cell does not divide repeatedly, it is no
kinases , the other class of oncogenes, they may promote either
threat, and if gene control is passed on, the cell will ultimately
kind of error. As a result, the cell will be stuck at an intermediate
state, repeatedly dividing and unable to find the next instruction
differentiate.
In the last decade we have seen the discovery of oncogenes,
in the developmental program.
We have known for decades that carcinogenesis involves two
which are derived from normal cellular genes but clearly able
biochemical events, initiation and promotion. Now that the
to cause malignant disease when inserted into cells by
retroviruses. Some of the oncogenes contain the genetic code
development of normal cells is becoming clearer, we are also
for proteins that resemble either growth factors or receptors for
beginning to understand how the two carcinogenic events
growth factors. Others are protein kinases
might be related to molecular processes
Presence of both errors
that add phosphate to cellular proteins.
in the cell. Further research should soon
I believe that oncogenes interfere with
give us a precise description of the specific
is necessary for fuJJ.,.blown
normal control gene function. Those in the
defects in individual human tumors. With
malignant disease.
that kind of knowledge, rational thera,
growth factor or receptor category probably
promote the first error, sending the cell repeatedly through DNA
peutic strategies to correct or bypass defective mechanisms
replication and mitosis without allowing informative testing of
in the cancer cell genome may be within reach.
cellular status or environment by the control program. As the

Spring Publication: Immunology and Cancer
Margaret L. Kripke, Ph.D., Kathryn O'Connor Research
Professor of Immunology, and Philip Frost, M.D., Ph.D.,
professor of medicine and cell biology, are the editors
of Immunology and Cancer to be published in May by the
University of Texas Press (297 pages, $47 .50).
The collected papers of last year's 38th Annual Symposium
on Fundamental Cancer Research by The University of Texas
M. D. Anderson Hospital and Tumor Institute at Houston, the
book contains 18 chapters by leading research groups on
investigations of immune recognition by T and B cells, cellular
communication and interaction, immune responses to cancer,
immunologic effector mechanisms, and immunologic approaches
to cancer therapy.
The nature and regulation of the immune system is "one of
the most rapidly advancing areas of biomedical research;' Kripke
and Frost state in their preface. "Recent findings on the genetic
and biochemical bases for immunologic recognition have
revolutionized our understanding of the principles governing the
immune system and have made us aware of the intricacies
involved in its regulation;' they write.
Understanding of the effects of immune responses on
carcinogenesis and tumor growth has lagged behind progress in
basic immunology, the editors point out. At this meeting,
participants shared information and reviewed recent advances
in several areas of immunology, particularly as they apply to
immune response against cancer.
The book highlights "the gap between basic immunology and
tumor immunology and points to areas where bridging of these
Vol. 31, No. 2

two disciplines can occur;' Kripke and Frost write. "We hope
that this information will stimulate analyses of how our better
understanding of the nature and regulation of the immune system
might be applied to cancer prevention, detection, and
treatment;' they conclude.
The book may be ordered by writing the University of Texas
Press, P.O. Box 7819, Austin, TX 78713 or by calling the
publisher's tolUree number for Texas, (800)252,3206, or
(512)472--4032.

Book on Colorectal Cancer Metastasis
Biology and Treatment of Colorectal Cancer Metastasis, edited
by Anthony J. Mastromarino, Ph.D., assistant vice president for
research, was recently published by Martinus Nijhoff (328 pages,
$47 .50).
Proceedings of the National Large Bowel Cancer Project's 1984
Houston conference, the book deals with issues ranging from
the biology of colorectal cancer metastasis to controversies in
treatment and prevention, criteria of response, and analyses of
failure.
The book contains 25 papers by research groups throughout
the United States, all examining, as Mastromarino writes,
"relevant questions related to the clinical management of
patients with hepatic metastases from colorectal cancer and the
important, but less well,defined issue, their quality of life; the
better design and evaluation of clinical trials; and the biologic
phenomena associated with metastasis:'

7

om LL SEX;:).l ' UOlSnOH

sexd.L 'U!lsny
t 19 "ON l!Ulldd

;:)nU;:)AV l ;:)Ull;:)g

OIVd
d3elS0d

·s·n

v(Z xog 8VxH
SUOJlE:)119nd :)!JJlU;:)J:)S JO lU;:)WUEd;:)a

Mental Health Conference: The Doctor as a Person
The Eleventh Annual Mental Health Conference, The Doctor
as a Person: Caring, Curing, Selling, Searching, is sponsored by
the UT MDAH Department of Pediatrics and will be held May
22 and 23 at the Holiday Inn Medical Center. It will be chaired
by Jan van Eys, Ph.D., M.D., Mosbacher Professor of Pediatrics
and head of the pediatrics division, who originated the series
in 1976 with a conference on The Truly Cured Child.
This was followed by yearly conferences spanning a broad
range of topics-from the 1977 conference, Research on Children:
Medical Imperatives, Ethical Quandaries, and Legal Constraints, to
Survival Beyond Cure last year.
This year's conference, van Eys said, "will examine how
physicians, as human beings, see themselves as providers of
medical care. Our presentations will focus on the inherent
conflict in roles and tasks that physicians must assume at various
times. In our discussions, we will use childhood cancer as the
paradigm of care for the helpless, medical management of life,
threatening illness, and guidance from medical scientific
thought."
John P. McGovern, M.D., director of the McGovern Allergy·
Clinic and president of the McGovern Foundation, will give
the keynote address, "Giving Care and Being a Physician"
during the opening session Thursday morning, May 22.

Faculty
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Lawrence S. Frankel, M.D., UT MDAH
James G . Haughton, M.D., City of Houston Health Department
James A. Knight, M.D., Louisiana State University, New Orleans
Harry Lipscomb, M.D., Bryan, Texas
John P. McGovern, M.D., McGovern Foundation
Robert F. Murray, M.D., Howard University, Washington
Donald Pinkel, M.D., UT MDAH
John Spinetta, Ph.D., San Diego State University, San Diego
David N. Sundwall, United States Senate
Jan van Eys, Ph.D., M.D., UT MDAH
Kenneth Vaux, D.theol., University of Illinois, Chicago
Andrew C. von Eschenbach, M.D., UT MDAH

Thursday, May 22
The Physician as Scientist
Morning-sessions on the need for medical
knowledge and "the dilemma of care by trial. "

The Physician as Bearer
of Special Knowledge
Afternoon-sessions on the physician as guardian of
public welfare, the physician and public health, and
the physician as bearer of good and bad news for the
patient.

Friday, May 23
The Physician as Care Giver
Morning- topics include the physician as servant,
the practice of medicine, the care giver as a pat ient.

The Physician as Healer
Afternoon-discussions of the physician as priest,
.and the goal of medicine. The epilogue, given by van
Eys, will sum up the conference and its lessons.

For more information, call or write
Office of Conference Services-HMB Box 13 1
U.T. M. D. Anderson Hospital and Tumor Institute
6723 Bettner Avenue, Houston, Texas 77030

(713) 792-2222
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